ReviewOncotarget2017
MicroRNAs in cancer metastasis and angiogenesis.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- MiR-24-3p as a prognostic indicator for multiple cancers: from a meta-analysis view.Bioscience reports · 2020Pooled it
- MicroRNA-VEGF axis in gastric cancer: a novel therapeutic frontier.Discover oncology · 2026Review
- Article
- MicroRNAs in cancer: biogenesis, biomarkers and therapeutic strategies.Frontiers in medicine · 2026Review
- Next-generation miRNA therapeutics: from computational design to translational engineering.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Comprehensive Evaluation of Usnic Acid as a Potential Drug Candidate for Triple-Negative Breast Cancer: Insights from Transcriptomic, Proteomic, and In Vivo Analyses.Molecules (Basel, Switzerland) · 2025Article
- Rational engineering of nanoplatforms with hierarchical targeting hepatic tumor and subcellular mitochondria for enhanced image-guided photodynamic therapy.Journal of nanobiotechnology · 2025Article
- Decoding the pancreatic cancer microenvironment: The multifaceted regulation of microRNAs.Clinical and translational medicine · 2025Review
- Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer.Medical oncology (Northwood, London, England) · 2025Review
- Exosomal Delivery of miR-155 Inhibitor can Suppress Migration, Invasion, and AngiogenesisCurrent medicinal chemistry · 2025Article
- Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression.Current cancer drug targets · 2025Article
- Exosomes derived from colorectal cancer cells take part in activation of stromal fibroblasts through regulating PHLPP isoforms.EXCLI journal · 2024Article
- MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype.Biomedicines · 2023Review
- Article
- MiRNA-146a-A Key Player in Immunity and Diseases.International journal of molecular sciences · 2023Review
- An update in the applications of exosomes in cancer theranostics: from research to clinical trials.Journal of cancer research and clinical oncology · 2023Review
- High eukaryotic initiation factor 5A2 expression predicts poor prognosis and may participate in the SNHG16/miR-10b-5p/EIF5A2 regulatory axis in head and neck squamous cell carcinoma.Journal of clinical laboratory analysis · 2023Article
- Comprehensive Analysis to Identify LINC00511-hsa-miR-625-5p-SEMA6A Pathway Fuels Progression of Skin Cutaneous Melanoma.International journal of genomics · 2023Article
- ceRNAR: An R package for identification and analysis of ceRNA-miRNA triplets.PLoS computational biology · 2022Article
- Circular RNA ROCK1, a novel circRNA, suppresses osteosarcoma proliferation and migration via altering the miR-532-5p/PTEN axis.Experimental & molecular medicine · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer metastasis is a malignant process by which tumor cells migrate from their primary site of origin to other organs. It is the main cause of poor prognosis in cancer patients. Angiogenesis is the process of generating new blood capillaries from pre-existing vasculature. It plays a vital role in primary tumor growth and distant metastasis. MicroRNAs are small non-coding RNAs involved in regulating normal physiological processes as well as cancer pathogenesis. They suppress gene expression by specifically binding to the 3'-untranslated region (3'-UTR) of their target genes. They can thus act as oncogenes or tumor suppressors depending on the function of their target genes. MicroRNAs have shown great promise for use in anti-metastatic cancer therapy. In this article, we review the roles of various miRNAs in cancer angiogenesis and metastasis and highlight their potential for use in future therapies against metastatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.